We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.14 | 3.37% | 4.30 | 429,001 | 16:35:05 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 3.80 | 4.80 | 3.80 | 3.80 | 3.80 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 5.03M | -2.44M | -0.0083 | -4.58 | 12.28M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:00:13 | O | 4,000 | 3.81 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 23/12/2024 | 07:08 | UK RNS | Proteome Sciences PLC Loan Facility, Trading Update & Directorate Change |
| 13/9/2024 | 06:00 | UK RNS | Proteome Sciences PLC Interim Results and Directorate Change |
| 16/5/2024 | 12:10 | UK RNS | Proteome Sciences PLC Result of AGM |
| 16/5/2024 | 11:23 | ALNC |  IN BRIEF: Proteome Sciences promises AGM return to growth in 2024 |
| 16/5/2024 | 06:00 | UK RNS | Proteome Sciences PLC AGM Statement |
| 26/4/2024 | 10:18 | ALNC | Proteome wins GBP500,000 deal to supply mass spectrometry services |
| 26/4/2024 | 06:00 | UK RNS | Proteome Sciences PLC Contract Win |
| 10/4/2024 | 10:26 | ALNC | Proteome Sciences shares drop as revenue plunges and swings to loss |
| 10/4/2024 | 06:00 | UK RNS | Proteome Sciences PLC Final Results |
Proteome Sciences (PRM) Share Charts1 Year Proteome Sciences Chart |
|
1 Month Proteome Sciences Chart |
Intraday Proteome Sciences Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 16/1/2025 | 14:04 | Proteome Sciences leading Alzheimer's technology. | 93,266 |
| 16/1/2025 | 09:10 | 2025 will be a record year for revenue and profits - shares will MULTIBAG | 65 |
| 13/1/2025 | 08:23 | Proteome, what next? (moderated) | 59,913 |
| 13/9/2024 | 08:30 | Does Fgnoms really have to say the same thing all the time thread | 27 |
| 13/5/2020 | 18:36 | Only worth 3p on fundamentals.... | 10 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-01-17 15:00:14 | 3.81 | 4,000 | 152.40 | O |
| 2025-01-17 12:07:50 | 3.80 | 392 | 14.90 | O |
| 2025-01-17 12:07:46 | 3.80 | 393 | 14.93 | AT |
| 2025-01-17 12:03:39 | 3.80 | 237 | 9.01 | O |
| 2025-01-17 12:03:33 | 3.80 | 20 | 0.76 | O |
| Top Posts |
|---|
Posted at 17/1/2025 08:20 by Proteome Sciences Daily Update Proteome Sciences Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker PRM. The last closing price for Proteome Sciences was 4.16p.Proteome Sciences currently has 295,182,056 shares in issue. The market capitalisation of Proteome Sciences is £11,216,918. Proteome Sciences has a price to earnings ratio (PE ratio) of -4.58. This morning PRM shares opened at 3.80p |
Posted at 13/1/2025 11:22 by z1co Thnx , wasjobberDifficult to answer that question. The company will be in a period of substantial growth which started in the 2nd half of last year , the share price increase is beginning to reflect this growth. We will see record revenue and profits from 2025 onwards , the share price will RISE many FOLDS from the current levels over the next few years. |
Posted at 10/1/2025 16:47 by z1co Just like the share price rise in 2023 , we could see 5.5p to 6p before a small retrace and then another rise towards 8p to 9p.Does Mr Market knows something we don't ? If trading 2025 is better than expectations, then share price will breach 10p by the time they announce full year results and could even surpass 20p during this calendar year. |
Posted at 05/1/2025 18:33 by z1co LOLYou're NOT doing too good , first you post lies about me that i have arrived out of nowhere ( which by the way you misspelled ) and now you posted another lie about me that i'm a ramper. Having sold PRM in 2023 i have been waiting patiently to buy the shares again on SOLID news , the trading update for H2 was the catalyst for me to BUY the shares. The strong momentum in H2 will continue throughout 2025 and 2026 and with share price at 3p this was a no brainer. This time the shares will RISE even more than 2023. |
Posted at 05/1/2025 16:09 by z1co 049baltYou're post 15 is definitely NOT realistic. The downtrend of 2023 and first half of 2024 is over , which saw the price decline from 9p to 2.5p.The share price has started to climb higher after the trading update. The CEO said that full year TMT revenue for 2024 will be considerably higher than 2023 which was £3.40m. Could you care to explain what in % terms the " CONSIDERABLE " increase would be ? |
Posted at 05/1/2025 14:47 by wellhonedhutch Welcome ZICO - Thank you for your posts which have been very helpful and a breath of fresh air. I do think it is time to buy more on the PRM statement and that the move to America is apparently going so well. I am also encouraged by the £500,000 contract awarded, with the prospect of more from that same company and contracts from others. However many us who have been bulls over the years have been disappointed so often. Maybe this is the moment for PRM to move forward and enjoy the momentum of the Proteomic market growing into the future. PRM certainly have some good products and we are in the right area. Hopefully Stroke may come good to this year. How I would love to see this. |
Posted at 30/12/2024 11:53 by z1co H2 must have been very strong that's why they acquired TWO mass spectrometers to cope with the huge demand in orders.The company will give more info regarding what the sales were in H2 when they issue the full year trading update for current year which ends 31/12/2024.Another record year for revenue and profits in 2025 will send the share price significantly higher than 10p. Share price UP nearly 20% today |
Posted at 23/12/2024 11:51 by z1co The share price will steadily rise throughout 2025 and 2026.In 2021 the share price reached 10p and 2023 nearly 9.50p. Hope this helps those that are still short on the stock! |
Posted at 27/11/2024 07:21 by wrighty41 Very surprised at the lack of notifiable commercial progress by PRM this year, as represented by the share price.Earlier in the year PRM said that 2024 would see a ‘return ro growth’. If this isn’t delivered then it will be a huge disappointment. W41 |
Posted at 13/9/2024 08:28 by stocktastic HelloI looked in on the PRM share price last night for the first time in many months. Funnily, just before the interim today. So, Mariola is off. Not too clear what she achieved? Services 'healthy' Hmmm, £40k revenue in 6 months is less than what my local plumber would get. So the company plods on. Still no real hope of investors getting returns.... Still crooks like pools2 spout made up ramps Nothing changes |
Posted at 22/7/2024 11:27 by sandcrab2 The excellent Fgnoms covered this 13 years ago“fgnoms30 Apr '11 - 10:28 - 14 of 26 0 0 0 Well here we are at the end of April and still no commercial money-making contracts have been signed. CJP at the time of the money raising reiterated break even for 2010, which would have required a few such contracts to have been signed in say late Q3 2010. So seven months on and NO such deals have been signed. I guess the important question is why? Of course we have suffered the same sorry story for the last 4 years on stroke. Yes 4 years ago contracts were imminent and apparently still are but we haven't been told why they haven't been signed. The obvious explanation is that PRM stroke biomarkers together with other panel constituents don't work well enough and therefore a stroke panel cannot be commercialised. Remember all those companies testing the PRM stroke biomarkers - and absolutely nothing has resulted. I think it would now be reasonable to assume that stroke is dead. So what about AD. Yes we are now at the same stage as stroke was 4 years ago. Tests are being carried out - but this time by PRM itself. This indicates to me that none of the big boys have any faith whatsoever in PRM's AD biomarkers - especially since the Dutch revelation that Clusterin isn't a predictive biomarker. So why does PRM continue to lead us on that a commercial deal is just around the corner. I find this bizarre. As PRM is now carrying out its own tests on its own panel nobody is going to sign anything until the results are known - which will probably be in H1 2012. And even then it really isn't feasible that a final saleable AD working panel will only contain PRM biomarkers, is it? So in my view we are years away from a working AD panel. So where does all this optimism come from - cloud cuckoo land imho. So before my next post we will know the 2010 results - a complete disaster no doubt. A loss of nearly £5m compared with target breakeven. 2011 is also looking like another £5m loss as I don't believe any commercial contracts will be signed. 2012 may not be much better either and thats when the cash runs out. So what will the share price be when all this is revealed next month? A very far cry from anything the rampers are saying thats for sure.” |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
